abrdn Life Sciences Investors files proxy materials

TL;DR

abrdn Life Sciences Investors filed proxy docs, no fee. Standard procedure.

AI Summary

abrdn Life Sciences Investors (formerly H&Q Life Sciences Investors and Tekla Life Sciences Investors) filed a Definitive Additional Materials proxy statement on May 24, 2024. This filing relates to the company's proxy materials and does not involve a fee, as indicated by the 'No fee required' checkbox. The company is incorporated in Massachusetts and its fiscal year ends on September 30.

Why It Matters

This filing is a routine administrative document for abrdn Life Sciences Investors, providing official notification to shareholders regarding proxy matters. It ensures compliance with SEC regulations for shareholder communication.

Risk Assessment

Risk Level: low — This filing is a routine administrative document (DEFA14A) and does not contain information about significant corporate actions, financial performance, or strategic changes that would typically indicate higher risk.

Key Players & Entities

• abrdn Life Sciences Investors (company) — Registrant
• H&Q Life Sciences Investors (company) — Former company name
• Tekla Life Sciences Investors (company) — Former company name
• 1900 MARKET STREET SUITE 200 PHILADELPHIA PA 19103 (company) — Business and mailing address
• MA (company) — State of incorporation
• 0930 (company) — Fiscal year end
• 6177728515 (company) — Business phone number

FAQ

Filing Documents

• tm2415427d1_defa14a.htm (DEFA14A) — 16KB
• tm2415427d1_defa14aimg002.jpg (GRAPHIC) — 8KB
• tm2415427d1_defa14aimg003.jpg (GRAPHIC) — 1KB
• tm2415427d1_defa14aimg004.jpg (GRAPHIC) — 7KB
• 0001104659-24-064983.txt ( ) — 40KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [ X ] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy Statement [ X ] Definitive Additional Materials [ ] Soliciting Material under §240.14a-12 abrdn Life Sciences Investors (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): [ X ] No fee required. [ ] Fee paid previously with preliminary materials. [ ] Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(l) and 0-11. abrdn Life Sciences Investors (NYSE: HQL) (formerly Tekla Life Sciences Investors) Shareholder Services Re: abrdn Life Sciences Investors (NYSE: HQL) formerly Tekla Life Sciences Investors Dear Shareholder: We have tried unsuccessfully to contact you, whether by mail or by phone, regarding a very important matter concerning your investment with abrdn Life Sciences Investors ( formerly Tekla Life Sciences Investors ). This matter pertains to important operating initiatives for the Fund for which we need your consideration and response. It is very important that we speak to you regarding this matter . Please call toll-free at 1-800-967-7574 between 9:00 a.m. and 10:00 p.m. Eastern Time, Monday through Friday. At the time of the call, please reference the Investor ID listed below. INVESTOR PROFILE: Investor ID: XXXXXXXX Security ID: XXXXXXXX Shares owned: XXXXXXXXX Household ID: XXXXXXXX There is no confidential information required and the call will only take a few moments of your time. Please contact us as soon as possible. Thank you for your time and consideration. Sincerely, Megan Kennedy Vice President and Secretary OFFICIAL BUSINESS This document relates to your investment in abrdn Life Sciences Investors (formerly Tekla Life Sciences Investors).

View Full Filing

View this DEFA14A filing on SEC EDGAR